Exclusive Product License AgreementExclusive Product License Agreement • May 5th, 2021 • Surface Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 5th, 2021 Company Industry JurisdictionThis Exclusive Product License Agreement (this “Agreement”) is made and entered into as of this 23rd day of March, 2021 (the “Effective Date”) by and between Vaccinex, Inc., having offices at 1895 Mt. Hope Avenue, Rochester NY 14620 USA (“Vaccinex”), and Surface Oncology, Inc. having offices at 50 Hampshire St, 8th Floor, Cambridge, MA 02139 (“Surface”). Vaccinex and Surface are sometimes referred to herein each individually as a “Party” and collectively as the “Parties.”